Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia

    Access Status
    Fulltext not available
    Authors
    Laurent, A.P.
    Siret, A.
    Ignacimouttou, C.
    Panchal, K.
    Diop, M.
    Jenni, S.
    Tsai, Y.C.
    Roos-Weil, D.
    Aid, Z.
    Prade, N.
    Lagarde, S.
    Plassard, D.
    Pierron, G.
    Daudigeos, E.
    Lecluse, Y.
    Droin, N.
    Bornhauser, B.C.
    Cheung, Laurence
    Crispino, J.D.
    Gaudry, M.
    Bernard, O.A.
    Macintyre, E.
    Barin Bonnigal, C.
    Kotecha, Rishi
    Geoerger, B.
    Ballerini, P.
    Bourquin, J.P.
    Delabesse, E.
    Mercher, T.
    Malinge, S.
    Date
    2020
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Laurent, A.P. and Siret, A. and Ignacimouttou, C. and Panchal, K. and Diop, M. and Jenni, S. and Tsai, Y.C. et al. 2020. Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. Clinical Cancer Research. 26 (13): pp. 3307-3318.
    Source Title
    Clinical Cancer Research
    DOI
    10.1158/1078-0432.CCR-19-3519
    ISSN
    1078-0432
    Faculty
    Faculty of Health Sciences
    School
    School of Pharmacy and Biomedical Sciences
    Funding and Sponsorship
    http://purl.org/au-research/grants/nhmrc/1142627
    URI
    http://hdl.handle.net/20.500.11937/81080
    Collection
    • Curtin Research Publications
    Abstract

    ©2020 American Association for Cancer Research. PURPOSE: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse, compared with other children with B-cell acute lymphoblastic leukemia (B-ALL). This highlights the lack of suitable treatment for Down syndrome children with B-ALL. EXPERIMENTAL DESIGN: To facilitate the translation of new therapeutic agents into clinical trials, we built the first preclinical cohort of patient-derived xenograft (PDX) models of DS-ALL, comprehensively characterized at the genetic and transcriptomic levels, and have proven its suitability for preclinical studies by assessing the efficacy of drug combination between the MEK inhibitor trametinib and conventional chemotherapy agents. RESULTS: Whole-exome and RNA-sequencing experiments revealed a high incidence of somatic alterations leading to RAS/MAPK pathway activation in our cohort of DS-ALL, as well as in other pediatric B-ALL presenting somatic gain of the chromosome 21 (B-ALL+21). In murine and human B-cell precursors, activated KRASG12D functionally cooperates with trisomy 21 to deregulate transcriptional networks that promote increased proliferation and self renewal, as well as B-cell differentiation blockade. Moreover, we revealed that inhibition of RAS/MAPK pathway activation using the MEK1/2 inhibitor trametinib decreased leukemia burden in several PDX models of B-ALL+21, and enhanced survival of DS-ALL PDX in combination with conventional chemotherapy agents such as vincristine. CONCLUSIONS: Altogether, using novel and suitable PDX models, this study indicates that RAS/MAPK pathway inhibition represents a promising strategy to improve the outcome of Down syndrome children with B-cell precursor leukemia.

    Related items

    Showing items related by title, author, creator and subject.

    • The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution
      Anderson, D.; Skut, P.; Hughes, Anastasia; Ferrari, E.; Tickner, J.; Xu, J.; Mullin, B.H.; Tang, D.; Malinge, S.; Kees, U.R.; Kotecha, Rishi ; Lassmann, T.; Cheung, Laurence (2020)
      © 2020, The Author(s). The bone marrow microenvironment (BMM) plays a key role in leukemia progression, but its molecular complexity in pre-B cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children, ...
    • Overview of health issues in school-aged children with down syndrome
      Thomas, K.; Girdler, Sonya; Bourke, J.; Deshpande, A.; Bathgate, Katherine; Fehr, S.; Leonard, H. (2010)
      Background: School-aged children with Down syndrome experience an array of medical conditions and health care problems. Although there have been vast improvements in the medical management of these conditions, they still ...
    • New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment
      Cheung, Laurence; Tickner, J.; Hughes, A.; Skut, P.; Howlett, M.; Foley, B.; Oommen, J.; Wells, J.; He, B.; Singh, S.; Chua, G.; Ford, J.; Mullighan, C.; Kotecha, R.; Kees, U. (2018)
      © 2018 The Author(s) The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.